The Washington, D.C.-based preclinical stage biotech company has developed MacroVax, an intracellular vaccine delivery technology that activates the immune system against cancer and other diseases by modulating chemical barriers within the tumor microenvironment. Immudicon's technology has shown promising results in vitro and in vivo, including T-cell specificity to tumor antigens, cytokine activation profiles, and early-stage prophylactic trials.